Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
Stefani Spranger(University of Chicago), Thomas F. Gajewski(University of Chicago)
Cited by 543
Related Papers
Impact of oncogenic pathways on evasion of antitumour immune responses
|Nature reviews. Cancer|2018|652
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|594
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
|Journal of Clinical Oncology|2018|382
Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
|Journal for ImmunoTherapy of Cancer|2019|157